Decoy Therapeutics
DCOY
8 hedge funds and large institutions have $227K invested in Decoy Therapeutics in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more ownership
Funds ownership: 0% → 0.01% (+0%)
11% less funds holding
Funds holding: 9 → 8 (-1)
29% less capital invested
Capital invested by funds: $321K → $227K (-$94.7K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$106K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.95K |
| 3 |
Renaissance Technologies
New York
|
+$3.98K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.49K |
DCOY Hedge Fund Activity: Q3 2023 in Review
8 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2023, worth a combined $227K — down 29% from $321K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DCOY and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 4 added.
The largest buyer was Armistice Capital, adding an estimated $106K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $1.49K sold.
- 8 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2023, down from 9 in Q2 2023.
- Funds reported $227K of Decoy Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Decoy Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $106K added.
- The largest Decoy Therapeutics seller in Q3 2023 was JP Morgan Chase, an estimated $1.49K sold.
Based on aggregated 13F filings for Q3 2023.